Denial - I get what you're saying but my point is that until...

Denial - I get what you're saying but my point is that until there is a statistically significant result - those "averages" are just down to chance and can be just down to luck and randomisation. While some people may still believe there to be a DMOAD benefit, the drug label and therefore partners will not / they can't.

As for your second question re professional indemnity. It's the same result as above. It's a moot point unless you can get something on a label, but if you are talking purely on pain and function which PPS at least seems to have some evidence of (mind you in a smaller population ((mild to mid pain patients only)), then yeah sure - but then you're just competing in a low price arena against $1 tablets which are easily prescribed and dispensed versus an injectable multiple times a week and requiring physician visits. Further to this, I personally haven't seen any studies proving that these other drugs (NSAIDS, OPIOIDS, HA, etc etc) accelerates the underlying pathology on a long-term basis aside from what mgmt have said.